欢迎来到麦多课文档分享! | 帮助中心 海量文档,免费浏览,给你所需,享你所想!
麦多课文档分享
全部分类
  • 标准规范>
  • 教学课件>
  • 考试资料>
  • 办公文档>
  • 学术论文>
  • 行业资料>
  • 易语言源码>
  • ImageVerifierCode 换一换
    首页 麦多课文档分享 > 资源分类 > PPT文档下载
    分享到微信 分享到微博 分享到QQ空间

    ALS-Management and Upcoming Clinical Trials.ppt

    • 资源ID:378213       资源大小:435.50KB        全文页数:46页
    • 资源格式: PPT        下载积分:2000积分
    快捷下载 游客一键下载
    账号登录下载
    微信登录下载
    二维码
    微信扫一扫登录
    下载资源需要2000积分(如需开发票,请勿充值!)
    邮箱/手机:
    温馨提示:
    如需开发票,请勿充值!快捷下载时,用户名和密码都是您填写的邮箱或者手机号,方便查询和重复下载(系统自动生成)。
    如需开发票,请勿充值!如填写123,账号就是123,密码也是123。
    支付方式: 支付宝扫码支付    微信扫码支付   
    验证码:   换一换

    加入VIP,交流精品资源
     
    账号:
    密码:
    验证码:   换一换
      忘记密码?
        
    友情提示
    2、PDF文件下载后,可能会被浏览器默认打开,此种情况可以点击浏览器菜单,保存网页到桌面,就可以正常下载了。
    3、本站不支持迅雷下载,请使用电脑自带的IE浏览器,或者360浏览器、谷歌浏览器下载即可。
    4、本站资源下载后的文档和图纸-无水印,预览文档经过压缩,下载后原文更清晰。
    5、试题试卷类文档,如果标题没有明确说明有答案则都视为没有答案,请知晓。

    ALS-Management and Upcoming Clinical Trials.ppt

    1、ALS-Management and Upcoming Clinical Trials,Abi Muthukumaran, MD Director of the ALS Program Cedars-Sinai Medical Center Los Angeles.,ALS Symptoms,Muscle weakness Atrophy StiffnessCramps Fasciculations,ALS Symptoms,Dysphagia Difficulty in swallowing Dysarthria Difficulty in speech Dysphonia Change i

    2、n voice quality Respiratory Insufficiency Emotional Lability,ALS Symptoms,Weight loss Depression Anxiety Memory loss Fatigue Pain Drooling of saliva,ALS,Spontaneous motor activity Cramps Fasciculations,Wasting of hands & arms in ALS,ALS Management,A multidisciplinary approach Physical/Occupational T

    3、herapy Speech Therapy Nutrition Assessment and Swallow evaluation Respiratory therapy/pulmonology Home Health Social Worker Palliative Care,Medical Management Riluzole,The only FDA approved drug for ALS treatment AAN Practice Advisory- Neurology 1997 Approved for use in the US, Europe- 1996 and Cana

    4、da 2000 Safe, fairly well tolerated Moderate efficacy Expensive ($10,000/year !),Riluzole,Riluzole,Monitor LFTs at baseline and every month for first 3 months, followed by every 3 months long term Reduces damage to motor neurons by decreasing the release of glutamate Prolongs survival by 3-4 months,

    5、 Cochran review 2005 Side effects include fatigue, nausea, diarrhoea and liver toxicity,Symptomatic Management,Important part of ALS treatment Several recent advances for symptom management Increase in survival and quality of life in patients seen in ALS centers,Symptomatic Management,Emotional labi

    6、lity (Pseudobulbar affect) Associated frequently with bulbar dysfunction Amitriptyline (TCA) Forshew and Bromberg 2003Fluvoxamine (SSRI) Dextromethorphan/Quinidine Patient and caregiver education ( AAN Practice Parameter - Guidelines for symptomatic management of ALS ),ALS Management,Spasticity Bacl

    7、ofen 10 mg po bid/tid and titrate up as tolerated Tizanidine- 4 mg po bid/tid Valium 20-40 mg po at bedtime Stretching of the muscles Baclofen pump for severe spasticity,ALS Management,Cramps and Fasciculations -Difficult to treat generally -Magnesium Slow Mag -Tonic water (quinine) -Chamomile tea ?

    8、 -Low dose baclofen -Low dose benzodiazepines,ALS Management,Treatment of Pain Can occur at any stage in the disease Neuropathic, Musckulosketetal, immobility Combination of drugs NSAIDS, Gabapentin, Pregabalin, TCAs Severe Pain Narcotics,ALS Management,Treatment of Fatigue Amantidine dose 100 mg Po

    9、 twice or three times daily Modafinil (Provigil)- 100 mg 1-2 times a day Treatment of other underlying causes ( thyroid dysfunction, anemia etc.),ALS Management,Insomnia Ambien Sedating antidepressants- Trazadone, Remeron Correcting underlying factors nocturnal hypoventilation, pain etc. Sleep hygei

    10、ne,ALS Management,Bowel and Bladder Dysfunction-Bladder Urgencies - Oxybutinin (detrol), Catheters -Constipation increase fiber in diet, hydration, stool softners, laxatives, enema if severe,Sialorrhea Management,Glycopyrrolate (Robunil)- 1-2 mg every 4 hours Benztropine, Amitriptyline Transdermal h

    11、yoscine patch Topical atropine drops - 1% every 4 hours Botox or Myobloc injection into the salivary glands Radiation therapy if very severe (AAN Practice Parameter- R. G Miller and Colleagues, revised Nov, 2006),Sialorrhea Management,ALS Management,Thick Mucus Production Increase Hydration Guiafene

    12、sin (robitussin) liquid or pill form Propananol ? Suctioning and cough assist device,ALS Management,Goal of therapy Maximize function Establish safe exercises without overexertion Improvement of quality of life Prevention of contractures Patient transfers and assistive devices/aids Fall precautions,

    13、ALS Management,Tremendous advances in technology Newer communication devices Sophisticated power wheel chairs Stair climbers Portable ramps Other durable medical equipments,Management of Dysphagia,Speech and swallow evaluation periodically in clinic Assessment of nutritional status High protein and

    14、high calorie diet Barium swallow, video swallow studyEarly discussion about PEG tube Referral to GI specialist,G Tube,Management of Dysphagia,Indications for G-tube Moderate to severe dysphagia Significant weight loss Recurrent pneumonia Declining respiratory status,Management of Respiratory Failure

    15、,FVC checks q 3 months in clinic by RT BIPAP if FCV 50 PPV Invasive ventilation/Tracheostomy when FVC 30 PPV Treating underlying infection Management of patient anxiety,Palliative Care,Palliative services involved early Hospice for patients with end stage ALS Comfort care and pain management Early D

    16、ecision making Advanced Directives,Upcoming Clinical Trials,Arimoclomol,Oct 2005, Phase IIa study completed. 80 patients participated, 10 centers (NorthEast ALS Consortium) Study Goal- safety and tolerability profile for the drug Thought to work by upregulating the heat-shock proteins and“molecular

    17、chaperones” in cells under oxidative stress Increased survival by 5 weeks in SOD-1 mouse model (by Univ of London),Nature Medicine, 2004,Arimoclomol,Results presented at the International ALS/MND meeting in Japan. Phase 2a study showed that the compound entered the BBB and CSF Phase 2b study with Ar

    18、imoclomol planned, to begin in summer 2008 390 patients, 30-35 sites,Ceftriaxone,Ceftriaxone study Phase II Goal- tolerability and safety when given over long periods of time Shown in animal models to increase survival by few weeks. Mechanism- crosses the BBB and increases the level of glutamate tra

    19、nsporter carrier protein to decrease the level of glutamate and cellular excitotoxicity,Ceftriaxone,60 patients initially, 10 US Centers First Stage- to study the level of drug in CSF Second stage to assess the safety profile when used over 16 weeks Third Stage Additional 540 patients will be enroll

    20、ed to study efficacy (ongoing) Drug is given IV through a central venous catheter,Negative Drug Trials,Vitamin E TCH346 Celebrex Creatine Indinavir Topiramate(topamax) Neurontin Minocycline,Manganoporphyrin,a novel antioxidant (AEOLUS) 38 percent increase in survival in SOD mouse large study underwa

    21、y. Small study with 30 patients showed safety. SC injection, 75 mg once a day.,Lithium for ALS Treatment,A small Italian study 44 pts Lithium and Riluzole vs Riluzole and placebo Slows progression of disease and 16 patients in lithium arm alive at 15 month follow up 29 % of patients died in placebo

    22、arm,Lithium and ALS,Mechanism of action Increases autophagy Increase in number of mitochondria- spinal cord of SOD1 mouse model Increased motor neuron density,Fig. 5. Effects of lithium treatment on disease symptom progression and survival in patients with ALS Fornai, Francesco et al. (2008) Proc. N

    23、atl. Acad. Sci. USA 105, 2052-2057,Lithium for ALS,A larger multicenter trial on the way 250 patients- NEALS, CALS NIH sponsored Expect to start this summer Double blinded placebo controlled randomized study Dosage- 150 mg po BID, upto 450 mg a day To maintain a serum drug level 0.4-0.8meq/litre,Lit

    24、hium for ALS,Primary outcome- disease progression A 6 point drop in ALSFRS FVC decline If lithium is effective, then placebo patients will be switched to the drug,Lithium and ALS,Side EffectsNausea, vomiting, fatigue, diarrhea, dizziness, weight gain, weakness, tremor, drowsiness and seizure at toxi

    25、c levels, irregular heart beat, renal failure, hypothyroidism,Other Studies,Diaphragm Pacing for respiratory muscle weakness to improve breathing (Cleveland)Larger clinical trial on the wayNutrition in ALS (phase 2 study, university of Kentucky),Exercise in ALS,There is emerging evidence that regula

    26、r exercise helps the rate of decline Still some conflicting data SOD mouse in treadmill 10 weeks increase in survival Vs no exercise But high intensity exercise is badMahoney,2004,Conclusions,Unprecedented number of clinical trials in ALS in one time Marked diversity in technology and targeting diff

    27、erent disease mechanisms. We need to improve patient access in multidisciplinary clinics and establish more clinical trials with the best study designs. Work with different organizations more closely ALSA, NIH, MDA and corporate sectors,Lou Gehrig,“Fans, for the past two weeks you have been reading about the bad break I got.Yet today I consider myself the luckiest man on the face of earth. I may have had a tough break, but I have an awful lot to live for”,Thank you for your patience,


    注意事项

    本文(ALS-Management and Upcoming Clinical Trials.ppt)为本站会员(arrownail386)主动上传,麦多课文档分享仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对上载内容本身不做任何修改或编辑。 若此文所含内容侵犯了您的版权或隐私,请立即通知麦多课文档分享(点击联系客服),我们立即给予删除!




    关于我们 - 网站声明 - 网站地图 - 资源地图 - 友情链接 - 网站客服 - 联系我们

    copyright@ 2008-2019 麦多课文库(www.mydoc123.com)网站版权所有
    备案/许可证编号:苏ICP备17064731号-1 

    收起
    展开